Novartis announces positive results from phase III KESTREL study of brolucizumab in diabetic macular oedema
In the study, brolucizumab met primary endpoint of non-inferiority to aflibercept in change in best-corrected visual acuity at 1-year mark and demonstrated improvement at the 6mg does in change of central subfield thickness from baseline between weeks 40 and 52.
Source:
Biospace Inc.
SPS commentary:
Brolucizumab, a single-chain antibody fragment, is currently licensed for the treatment of adults with neovascular (wet) age-related macular degeneration.